Brazilian healthtech Memed, a leader in digital medical prescriptions, has secured R$ 80 million in a new funding round. The investment was co-led by venture capital firms DGF and BridgeOne, with participation from controlling shareholder DNA Capital. This capital will accelerate Memed's expansion and the integration of artificial intelligence into its clinical support platform.
Strategic Investment for AI-Powered Growth
The R$ 80 million will be primarily allocated to bolstering the company's engineering, product, and data science departments. Memed plans to hire new talent in these areas to drive its next phase of innovation. This investment supports the company's ambition to become a comprehensive digital infrastructure for Brazil's healthcare ecosystem.
According to CEO Rodolfo Chung, the focus has shifted from digitizing prescriptions to delivering gains in clinical productivity and quality. The company aims to embed AI as a core component of the prescribing process, offering real-time decision support. This includes providing physicians with context on drug interactions, appropriate dosages, and other clinical alerts.
From Breakeven to Market Leadership
This new chapter follows a significant financial turnaround, as the company reached breakeven in mid-2025 after 13 years. Under Chung's leadership, Memed has become profitable and projects reaching R$ 100 million in revenue by 2026. This financial discipline has established a solid foundation for the company's ambitious growth strategy.
Memed holds a commanding 60% share of the digital prescription market, serving 150,000 doctors monthly and issuing 100 million prescriptions annually. Despite this, the market has significant room for growth, as only 15% of prescriptions in Brazil are digital. This untapped potential represents a major opportunity for the company's continued expansion and market penetration.
Expanding Services and Team
Beyond prescriptions, Memed is developing new services to enhance patient care and support physicians. These initiatives include medication reminders for patients with chronic illnesses and educational content explaining drug side effects. The goal is to create tools that doctors can share with patients post-consultation to improve treatment adherence.
To power this expansion, the company is growing its team from 90 employees last year to a projected 180 by year-end. The recruitment drive is focused on professionals with expertise in artificial intelligence who can navigate the healthcare sector's requirements. This investment in specialized talent is critical to building a more robust and intelligent platform.
Investor Confidence and Future Outlook
Investor confidence in Memed's vision is strong, with partners highlighting its established network and valuable structured clinical data. Frederico Greve of DGF noted the company's potential to become essential infrastructure for the sector. Vinicius Portas of BridgeOne added that Memed's data asset is increasingly valuable as AI in health becomes a reality.
Looking ahead, Memed plans to launch new AI-powered features and deepen its integration with electronic health records and hospital systems. Regulatory approval for the digital issuance of controlled substance prescriptions also opens new avenues for growth. With these developments, the company is on a trajectory to potentially achieve unicorn status within five years.
This R$ 80 million funding round marks a pivotal moment for Memed, fueling its transformation into an AI-driven clinical intelligence platform. By focusing on enhancing physician workflows and improving patient safety, the company is poised to lead the digital evolution of healthcare in Brazil. The investment solidifies its mission to build a comprehensive digital health ecosystem for the entire country.